PHRM.L Regulatory News (PHRM)

Phorm, Inc.

AIM Block Admission Update

08 October 2010

Phorm, Inc.

('Phorm' or the 'Company')

Block Admission Return

Phorm (AIM: PHRM and PHRX), the internet personalisation technology company, is

providing an update to its block admission filed on 9 April 2010 (the "Scheme").

For the period from 9 April 2010 to 8 October 2010, Phorm did not issue any securities under the Scheme and has the following balance of not yet issued securities under the Scheme:

As of 8 October 2010, the Company had an issued share capital of 18,479,907 common

shares with a par value of $0.001 each, of which 17,472,014 are trading on AIM under

the ticker PHRM, the restricted line and 1,007,893 are trading on AIM under the ticker PHRX, the unrestricted Line. A further 45,000 common shares are held in treasury.

About Phorm:

Phorm is a global personalisation technology company that makes content and advertising more relevant to the consumer. Phorm's innovative platform preserves user privacy and delivers a more interesting online experience. Phorm's partners include leading ISPs, Publishers, Ad Networks and Advertisers.

Phorm is a Delaware, US incorporated company, with offices in Seoul, Moscow, Sao Paulo and London. The Company was admitted to the AIM market of the London Stock Exchange in 2004 and has over 150 employees and direct contractors. For more information, please visit: www.phorm.com

Enquiries:

Phorm, Inc.

Andy Croxson (analysts & investors) +44 20 7297 2326

Alex Laity (media) +44 20 7297 2710

Citigate Dewe Rogerson +44 20 7638 9571

Justin Griffiths

Simon Rigby

Canaccord Genuity Limited +44 20 7050 6500

(Nominated Adviser)

Mark Williams

Andrew Chubb